Drug Safety

Case Reports and Drug Safety
pp. 643-645(3)
Author: EP van Puijenbroek,

Long-Acting β2-Agonists in Asthma: Not so SMART?
pp. 647-656(10)
Authors: Currie, Graeme P.; Lee, Daniel K.C.; Lipworth, Brian J.

Pharmacovigilance during the Pre-Approval Phases: An Evolving Pharmaceutical Industry Model In Response To ICH E2E, CIOMS VI, FDA and EMEA/CHMP Risk-Management Guidelines
pp. 657-673(17)
Authors: Hartford, Craig G.; Petchel, Kasia S.; Mickail, Hani; Perez-Gutthann, Susana; McHale, Mary; Grana, John M.; Marquez, Paula

Safety of Etanercept in Psoriasis: A Critical Review
pp. 675-685(11)
Authors: Carazo, Jose L. Sánchez; Laura Mahiques Santos,; Vicente Oliver Martinez,

Serious Skin Reactions and Selective COX-2 Inhibitors: A Case Series From Prescription-Event Monitoring In England
pp. 687-696(10)
Authors: Layton, Deborah; Marshall, Vanessa; Boshier, Andrew; Friedmann, Peter; Saad AW Shakir,

Can Decisional Algorithms Replace Global Introspection in the Individual Causality Assessment of Spontaneously Reported ADRs?
pp. 697-702(6)
Authors: Macedo, Ana F.; Marques, Francisco B.; Ribeiro, Carlos F.

Effect of Ezetimibe and/or Simvastatin on Coenzyme Q10 Levels in Plasma: A Randomised Trial
pp. 703-712(10)
Authors: Berthold, Heiner K.; Naini, Ali; Salvatore Di Mauro,; Hallikainen, Maarit; Gylling, Helena; Krone, Wilhelm; Gouni-Berthold, Ioanna

Drug-Induced Thrombocytopenia: A Population Study
pp. 713-721(9)
Authors: Berg, Maarten J. ten; Huisman, Albert; Souverein, Patrick C.; Schobben, Alfred F.A.M.; Egberts, Antoine C.G.; van Solinge, Wouter W.; Patricia M.L.A. van den Bemt,

Clinical Risk Management in Dutch Community Pharmacies: The Case of Drug-Drug Interactions
pp. 723-732(10)
Authors: Buurma, Henk; De Smet, Peter A.G.M; Egberts, Antoine C.G.

An Industry Perspective on the Erice Declaration and Risk Minimisation Plans
pp. 733-734(2)
Authors: Ingate, Simon; Tranter, Deborah; Banerjee, Anjan; Hobbs, Andrew